2q26rs7578326226728897IRS10.641.111.002(74) 3p25rs180128212368125PPARG0.851.231.005(73) 3p14rs460710364686944ADAMTS90.761.101.002(73) 3q13–q21rs11708067124548468ADCY50.771.121.002(18) 3q27rs4402960186994381IGF2BP20.311.111.002(73) 4p16rs100101316343816WFS10.591.141.004(73) 5q13rs445705376460705ZBED30.261.081.001(74) 6p22rs1094639820769013CDKAL10.331.091.002(73) 7p21rs219134915030834DGKB/TMEM1950.471.061.001(18) 7p15rs86474528147081JAZF10.501.081.001(73) 7p15rs460751744202193GCK0.21.071.001(18) 7q32rs972283130117394KLF140.551.071.001(74) 8q22rs89685496029687TP53INP10.481.061.001(74) 8q24rs13266634118253964SLC30A80.681.121.003(73) 9p21rs1081166122124094CDKN2A/B0.841.171.003(73) 9q21rs1329213681141948CHCHD90.931.111.001(74) 10p13rs1277979012368016CDC123/CAMK1D0.181.111.002(73) 10q23rs501548094455539HHEX/IDE0.591.101.002(73) 11p15rs23344991653428DUSP80.411.081.001(32) 11p15rs2313622648047KCNQ10.521.081.001(74) 11p15rs22378922796327KCNQ10.341.421.031(73) 11p15rs521917366148KCNJ110.391.151.005(73) 11q13rs155222472110746CENTD20.881.141.002(74) 11q21rs1083096392348358MTNR1B0.301.091.001(73) 12q14rs153134364461161HMGA20.11.11.001(74) 12q14–q21rs796158169949369TSPAN8/LGR50.271.061.001(73) 12q24rs7957197119945069HNF1A0.851.071.001(74) 15q25rs1163439778219277ZFAND60.61.061.001(74) 15q26rs804268089322341PRC10.221.071.001(74) 16q12rs805013652373776FTO0.381.211.009(73) 17cen–q21.3rs75721033170628HNF1B (TCF2)0.381.101.002(73) Xq28rs5945326152553116DUSP90.211.271.011(74)RA, rheumatoid arthritis; T1D, type 1 diabetes; CD, Crohn's disease; T2D, type 2 diabetes; RAF, risk allele frequency in controls; OR, odds ratio.Sibling recurrence risk ratio (λs) was calculated using the formula: where q is the risk allele frequency, p = 1 − q, and γ is the genotype relative risk under the additive model.
